Page 50 - MI-2-1

Microbes & Immunity iPSC-derived NK cell immunotherapy

natural killer (upCAR-NK) cells for B-cell malignancy 111. Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered
treatment. Cancer Res. 2024;84(6_Supplement):1330. to express IL-15 and a CD19-targeted CAR show long-
term persistence and potent antitumor activity. Leukemia.
doi: 10.1158/1538-7445.Am2024-1330
2018;32(2):520-531.
102. Bachanova V, Cayci Z, Lewis D, et al. Initial clinical activity
of FT596, a first-in-class, multi-antigen targeted, off-the- doi: 10.1038/leu.2017.226
shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/ 112. Luanpitpong S, Poohadsuan J, Klaihmon P, Issaragrisil S.
refractory B-cell lymphoma. Blood. 2020;136(Supplement 1):8. Selective cytotoxicity of single and dual anti-CD19 and
anti-CD138 chimeric antigen receptor-natural killer
doi: 10.1182/blood-2020-141606
cells against hematologic malignancies. J Immunol Res.
103. Ramachandran I, Rothman S, Clausi M, et al. Multiple 2021;2021:5562630.
doses of Cnty-101, an iPSC-derived allogeneic CD19
targeting CAR-NK product, are safe and result in tumor doi: 10.1155/2021/5562630
microenvironment changes associated with response: A case 113. Portillo AL, Hogg R, Poznanski SM, et al. Expanded human
study. Blood. 2023;142(Supplement 1):1654-1654. NK cells armed with CAR uncouple potent anti-tumor
activity from off-tumor toxicity against solid tumors.
doi: 10.1182/blood-2023-182313
iScience. 2021;24(6):102619.
104. Cichocki F, Bjordahl R, Gaidarova S, et al. iPSC-derived NK
cells and anti-PD-1 antibody synergize to enhance T Cell doi: 10.1016/j.isci.2021.102619
cytokine and cytolytic responses against multiple tumors. 114. Chen SW, Hung YS, Fuh JL, et al. Efficient conversion
Blood. 2018;132(Supplement 1):730. of human induced pluripotent stem cells into microglia
by defined transcription factors. Stem Cell Reports.
doi: 10.1182/blood-2018-99-114893
2021;16(5):1363-1380.
105. Hong D, Patel S, Patel M, et al. 380 Preliminary results of an
ongoing phase I trial of FT500, a first-in-class, off-the-shelf, doi: 10.1016/j.stemcr.2021.03.010
induced pluripotent stem cell (iPSC) derived natural killer 115. Guo R, Hu F, Weng Q, et al. Guiding T lymphopoiesis from
(NK) cell therapy in advanced solid tumors. J Immunother pluripotent stem cells by defined transcription factors. Cell
Cancer. 2020;8(Suppl 3):A231-A232. Res. 2020;30(1):21-33.
doi: 10.1136/jitc-2020-SITC2020.0380 doi: 10.1038/s41422-019-0251-7
106. Patel K, Bachanova V, Goodman AM, et al. Phase I 116. Rothhammer V, Quintana FJ. The aryl hydrocarbon receptor:
study of FT516, an off-the-shelf iPSC-derived NK cell An environmental sensor integrating immune responses in
therapy, in combination with rituximab in patients health and disease. Nat Rev Immunol. 2019;19(3):184-197.
with relapsed/refractory B-Cell lymphoma. Blood. doi: 10.1038/s41577-019-0125-8
2021;138(Supplement 1):3873.
117. Piwarski SA, Thompson C, Chaudhry AR, et al. The putative
doi: 10.1182/blood-2021-151520
endogenous AHR ligand ITE reduces JAG1 and associated
107. Xu Y, Liu Q, Zhong M, et al. 2B4 costimulatory domain NOTCH1 signaling in triple negative breast cancer cells.
enhancing cytotoxic ability of anti-CD5 chimeric antigen Biochem Pharmacol. 2020;174:113845.
receptor engineered natural killer cells against T cell doi: 10.1016/j.bcp.2020.113845
malignancies. J Hematol Oncol. 2019;12(1):49.
118. Hezaveh K, Shinde RS, Klötgen A, et al. Tryptophan-derived
doi: 10.1186/s13045-019-0732-7
microbial metabolites activate the aryl hydrocarbon receptor
108. Topfer K, Cartellieri M, Michen S, et al. DAP12-based in tumor-associated macrophages to suppress anti-tumor
activating chimeric antigen receptor for NK cell tumor immunity. Immunity. 2022;55(2):324-340.e8.
immunotherapy. J Immunol. 2015;194(7):3201-3012.
doi: 10.1016/j.immuni.2022.01.006
doi: 10.4049/jimmunol.1400330
119. Shin JH, Zhang L, Murillo-Sauca O, et al. Modulation of
109. Xiao L, Cen D, Gan H, et al. Adoptive transfer of NKG2D natural killer cell antitumor activity by the aryl hydrocarbon
CAR mRNA-engineered natural killer cells in colorectal receptor. Proc Natl Acad Sci U S A. 2013;110(30):12391-12396.
cancer patients. Mol Ther. 2019;27(6):1114-1125.
doi: 10.1073/pnas.1302856110
doi: 10.1016/j.ymthe.2019.03.011
120. Trikha P, Moseman JE, Thakkar A, et al. Defining the AHR-
110. Leivas A, Valeri A, Cordoba L, et al. NKG2D-CAR- regulated transcriptome in NK cells reveals gene expression
transduced natural killer cells efficiently target multiple programs relevant to development and function. Blood Adv.
myeloma. Blood Cancer J. 2021;11(8):146. 2021;5(22):4605-4618.
doi: 10.1038/s41408-021-00537-w doi: 10.1182/bloodadvances.2021004533

Volume 2 Issue 1 (2025) 42 doi: 10.36922/mi.5653